Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Oncology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(14)70161-5PMID 24827808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

  2013cited by this paper
• Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

  2013cited by this paper
• High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

  2013cited by this paper
• Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

  2013cited by this paper
• Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

  2013cited by this paper
• Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten

  2013cited by this paper
• Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

  2013cited by this paper
• The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

  2012cited by this paper
• Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

  2012cited by this paper
• Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

  2012cited by this paper
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

  2012cited by this paper
• Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

  2012cited by this paper
• Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.

  2011cited by this paper
• Allogeneic transplantation for lymphoma.

  2011cited by this paper
• Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

  2011cited by this paper
• Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

  2011cited by this paper
• Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

  2011cited by this paper
• Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

  2010cited by this paper
• Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

  2009cited by this paper
• Rituximab reduces the incidence of acute graft-versus-host disease.

  2009cited by this paper
• Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

  2009cited by this paper
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

  2009cited by this paper
• Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

  2009cited by this paper
• Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

  2008cited by this paper
• Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

  2007cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

  2005cited by this paper
• Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect

  2004cited by this paper
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

  2003cited by this paper
• An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

  2003cited by this paper
• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

  2002cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

  1998cited by this paper
• Evaluation of experiments with adaptive interim analyses.

  1994cited by this paper
• The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation

  1991cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

  1987cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

  1987cited by this paper
• Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

  1980cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis After Peripheral Blood Stem Cell HLA Identical Transplantation in Patients with Lymphoma: A Prospective Observational Study

  2025cites this paper
• From stem cell transplantation to stem cell-based drug delivery systems targeting hematological malignancies: recent advances and clinical considerations

  2025cites this paper
• Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

  2025cites this paper
• Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

  2025cites this paper
• Pharmacological Maintenance Therapies After Allogeneic Hematopoietic Cell Transplantation.

  2025cites this paper
• Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)

  2025cites this paper
• High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma—Is There Still a Role?

  2024cites this paper
• The Effect of the Pre‐Transplant Disease Status on the Outcome for Recipients of T‐Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas

  2024cites this paper
• Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning

  2024cites this paper
• Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

  2024cites this paper
• Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial

  2023cites this paper
• Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

  2023cites this paper
• Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy

  2023cites this paper
• Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?

  2023cites this paper
• Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

  2022cites this paper
• busulfan– cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial

  2022cites this paper
• The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy

  2022cites this paper
• Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study

  2022cites this paper
• Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical t

  2022cites this paper
• [Role of allogeneic hematopoietic cell transplantation after anti-CD19 CAR T-cell treatment: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

  2022cites this paper
• Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

  2022cites this paper
• Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  2022cites this paper
• Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma

  2022cites this paper
• Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.

  2022cites this paper
• Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation

  2021cites this paper
• Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases

  2021cites this paper
• The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis

  2021cites this paper
• Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report

  2021cites this paper
• Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years

  2021cites this paper
• Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

  2021cites this paper
• Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma

  2021cites this paper
• The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

  2020cites this paper
• Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma

  2020cites this paper
• A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

  2020cites this paper
• CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.

  2020cites this paper
• Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?

  2020influential citation
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation

  2020cites this paper
• Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

  2020cites this paper
• Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

  2019cites this paper
• The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.

  2019cites this paper
• Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

  2019cites this paper
• PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

  2019cites this paper
• Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States

  2019cites this paper
• Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

  2019cites this paper
• Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel

  2019cites this paper
• Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation

  2019cites this paper
• Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma

  2019cites this paper
• Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

  2019cites this paper
• Diffuses großzelliges B-Zell-Lymphom: Primär- und Rezidivtherapie

  2019cites this paper
• Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

  2019cites this paper
• Standard of Care in First-Line Therapy of DLBCL

  2018cites this paper
• Diffuse large B-cell lymphoma.

  2018cites this paper
• Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease

  2018cites this paper
• A comprehensive assessment of immunophenotyping performed in cryopreserved peripheral whole blood

  2018cites this paper
• Prevention and Treatment of Relapse by Drugs

  2018cites this paper
• Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

  2018cites this paper
• Diffuse Large B-Cell Lymphoma

  2018cites this paper
• Diffuse Large B-Cell Lymphoma

  2018cites this paper
• New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

  2017cites this paper
• Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

  2017cites this paper
• Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

  2017cites this paper
• Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era

  2017cites this paper
• Mechanistic approaches for the prevention and treatment of chronic GVHD.

  2017cites this paper
• Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma

  2017cites this paper
• Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas

  2017cites this paper
• Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

  2017cites this paper
• Lymphome bei rheumatischen Erkrankungen

  2017cites this paper
• Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

  2017cites this paper
• The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease

  2017cites this paper
• High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era.

  2017cites this paper
• Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial

  2017cites this paper
• Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

  2017cites this paper
• [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

  2017cites this paper
• How I manage peripheral T‐cell lymphoma, not otherwise specified and angioimmunoblastic T‐cell lymphoma: current practice and a glimpse into the future

  2017influential citation
• Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.

  2016cites this paper
• Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

  2016cites this paper
• Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments

  2016cites this paper
• Bridging to Transplant in Diffuse Large B Cell Lymphoma

  2016cites this paper
• Stellenwert und Perspektiven der hämatopoetischen Stammzelltransplantation bei malignen hämatologischen Systemerkrankungen

  2016cites this paper
• Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

  2016cites this paper
• Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma

  2016cites this paper
• Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation.

  2016cites this paper
• Nine-year change in statistical design, profile, and success rates of Phase II oncology trials

  2016cites this paper
• Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

  2016cites this paper
• Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

  2016cites this paper
• Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

  2015cites this paper
• Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

  2015cites this paper
• Tandem Transplantations in Lymphoma--Best of Both Worlds.

  2015cites this paper
• Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant

  2015cites this paper
• Stammzelltransplantation bei malignen Lymphomen

  2015cites this paper
• Primary refractory diffuse large B cell lymphoma in the rituximab era

  2015cites this paper
• Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

  2015cites this paper
• Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma

  2015cites this paper
• Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma

  2015cites this paper
• More than Memory: Potential of Adaptive Natural Killer Cells.

  2015cites this paper
• Rezidivtherapie aggressiver Lymphome

  2015cites this paper
• Indikationen für die allogene Stammzelltransplantation

  2015cites this paper
• Functional Analyses of Anti-B-Cell Antibodies Used to Treat Lymphoma

  2015cites this paper
• Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

  2014influential citation